spot_img
Thursday, May 19, 2022
More
    HomeHealthCompany was ‘wrong’ about initial Aduhelm price

    Company was ‘wrong’ about initial Aduhelm price

    -

    [ad_1]

    Biogen CEO Michel Vounatsos acknowledged Monday that the corporate was “improper” to cost its Alzheimer’s illness remedy Aduhelm at $56,000 a 12 months, however added that its determination to later slash the fee practically in half was “brave.”

    Talking nearly on the J.P. Morgan Healthcare Convention, Vounatsos described the corporate’s flagging income and the disastrous launch of Aduhem as “near-term challenges [that] usually are not defining Biogen,” and harassed “the corporate’s fundamentals are very sturdy.”

    Unlock this text by subscribing to STAT+ and luxuriate in your first 30 days free!

    GET STARTED



    [ad_2]

    Source link

    Related articles

    Stay Connected

    0FansLike
    0FollowersFollow
    3,318FollowersFollow
    0SubscribersSubscribe
    spot_img

    Latest posts